Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease

NCT02913508 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis
Crohn's Disease

Interventions

DRUG: Vedolizumab intravenous injection
DRUG: Vedolizumab subcutaneous injection

Sponsor

Takeda